Exosomal PD-L1 predicts response with immunotherapy in NSCLC patients.
Yuting WangXiaomin NiuYirui ChengYanshuang ZhangLiliang XiaWeiliang XiaShun LuPublished in: Clinical and experimental immunology (2022)
Immune Check-Point Inhibitors (ICIs) have shown remarkable promise in treating tumors, including non-small cell lung cancer (NSCLC). Nevertheless, the treatment response rate is low. Studies have found that the high expression of exosomal PD-L1 is one of the reasons for the low treatment response. Therefore, this study focused on the relationship between the exosomal PD-L1 and the clinical response to immunotherapy in NSCLC patients to evaluate whether it could be used as a biomarker to predict the efficacy of ICIs. In this study, clinical information and blood samples of 149 NSCLC patients receiving ICIs were collected. The expression level of exosomal PD-L1 was detected by enzyme-linked immunosorbent assay method, and the relationship between exosomal PD-L1 and the efficacy of ICIs was explored. Overall, our study found that the expression level of exosomal PD-L1 was lower at pre-treatment, or the max fold increasing change higher at 3-6 weeks had a higher disease control rate and longer progression-free survival. It revealed that the exosomal PD-L1 was associated with the treatment response of patients using ICIs and provided a new tool for the evaluation of clinical efficacy of lung cancer immunotherapy.
Keyphrases
- end stage renal disease
- small cell lung cancer
- ejection fraction
- chronic kidney disease
- newly diagnosed
- poor prognosis
- prognostic factors
- healthcare
- free survival
- patient reported outcomes
- social media
- brain metastases
- deep learning
- single cell
- smoking cessation
- tyrosine kinase
- patient reported
- epidermal growth factor receptor